Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Ticagrelor Orodispersible vs Immediate-release Tablets
NCT02400333Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ticagrelor in acute coronary syndrome (ACS) (4 arms), sponsored by AstraZeneca. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time Zero to Time of Last Quantifiable Analyte Concentration and 1 more. Started Jun 2015; status: completed.
02
Drugs
ticagrelor
03
Conditions
acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT02400333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02400333.